Immune monitoring of pancreatic islet graft: Towards a better understanding, detection and treatment of harmful events

Expert Opinion on Biological Therapy

Volumn 11, Issue 1, 2011, Pages 55-66

  Lacotte, Stéphanie ^a   Berney, Thierry ^a   Shapiro, Am James ^b   Toso, Christian ^a  

^a UNIVERSITY OF GENEVA   (Switzerland)

^b UNIVERSITY OF ALBERTA   (Canada)

Author keywords

alloimmunity; autoimmunity; immune monitoring; immunosuppression; islet transplantation

Indexed keywords

ADENOSINE TRIPHOSPHATE; ALLOANTIBODY; AUTOANTIBODY; CD20 ANTIBODY; CD30 ANTIGEN; GAMMA INTERFERON; GLUCOCORTICOID INDUCED TUMOR NECROSIS FACTOR RECEPTOR; GLUTAMATE DECARBOXYLASE 65; GLUTAMATE DECARBOXYLASE 65 ANTIBODY; GRANZYME B; HLA A2 ANTIGEN; HLA ANTIGEN CLASS 1; HLA ANTIGEN CLASS 2; HLA DR ANTIGEN; IMMUNOGLOBULIN; INSULIN ANTIBODY; INSULINOMA ASSOCIATED PROTEIN 2 ANTIBODY; MONOCYTE CHEMOTACTIC PROTEIN 1; T LYMPHOCYTE RECEPTOR; THYMOCYTE ANTIBODY; TRANSCRIPTION FACTOR FOXP3; UNCLASSIFIED DRUG;

ACCURACY; ADAPTIVE IMMUNITY; ALLOIMMUNITY; ANTIBODY DETECTION; AUTOIMMUNITY; CD4+ T LYMPHOCYTE; CELLULAR IMMUNITY; CLINICAL PRACTICE; CYTOTOXIC T LYMPHOCYTE; ENZYME LINKED IMMUNOSPOT ASSAY; GENE EXPRESSION; GRAFT RECIPIENT; HLA TYPING; HUMAN; HUMORAL IMMUNITY; IMMUNOASSAY; IMMUNOLOGICAL MONITORING; IMMUNOSUPPRESSIVE TREATMENT; INFLAMMATION; INSTANT BLOOD MEDIATED INFLAMMATORY REACTION; LYMPHOCYTE PROLIFERATION; MIXED LYMPHOCYTE CULTURE; PANCREAS ISLET TRANSPLANTATION; PERIPHERAL BLOOD MONONUCLEAR CELL; PRE T LYMPHOCYTE; PREDICTION; RECURRENT DISEASE; REVIEW; TREATMENT OUTCOME;

AUTOANTIBODIES; DIABETES MELLITUS, TYPE 1; HUMANS; IMMUNITY, INNATE; ISLETS OF LANGERHANS TRANSPLANTATION; MONITORING, PHYSIOLOGIC; POSTOPERATIVE PERIOD; T-LYMPHOCYTES, CYTOTOXIC;

EID: 78650056944     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.2011.536530     Document Type: Review

References (96)

1. Shapiro AM, Lakey JR, Ryan EA, et al. Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen. N Engl J Med 2000;343:230-8
2. Toso C, Baertschiger R, Morel P, et al. Sequential kidney/islet transplantation: Efficacy and safety assessment of a steroid-free immunosuppression protocol. Am J Transplant 2006;6:1049-58
3. Ryan EA, Paty BW, Senior PA, et al. Five-year follow-up after clinical islet transplantation. Diabetes 2005;54:2060-9
4. Barshes NR, Wyllie S, Goss JA. Inflammation-mediated dysfunction and apoptosis in pancreatic islet transplantation: Implications for intrahepatic grafts. J Leukoc Biol 2005;77:587-97
5. Roep BO, Stobbe I, Duinkerken G, et al. Auto- and alloimmune reactivity to human islet allografts transplanted into type 1 diabetic patients. Diabetes 1999;48:484-90
6. Monti P, Scirpoli M, Maffi P, et al. Islet transplantation in patients with autoimmune diabetes induces homeostatic cytokines that expand autoreactive memory T cells. J Clin Invest 2008;118:1806-14
7. Nir T, Melton DA, Dor Y. Recovery from diabetes in mice by beta cell regeneration. J Clin Invest 2007;117:2553-61
8. Campbell PM, Salam A, Ryan EA, et al. Pretransplant HLA antibodies are associated with reduced graft survival after clinical islet transplantation. Am J Transplant 2007;7:1242-8
9. Shapiro AMJ, Koh A, Salam A, et al. Impact of different induction therapies on long term durability of insulin independence after clinical islet transplantation. Am J Transplant 2008;8(Suppl 2):234
10. Shapiro AMJ, Koh A, Kin T, et al. Outcomes following alemtuzumab induction in clinical islet transplantation. Am J Transplant 2008;8(Suppl 2):235
11. Posselt A, Szot G, Frassetto L, et al. Islet Allograft survival in type 1 diabetics using a calcineurin-free protocol based on efalizumab and sirolimus. Am J Transplant 2008;8(Suppl 2):235
12. Bellin MD, Kandaswamy R, Parkey J, et al. Prolonged insulin independence after islet allotransplants in recipients with type 1 diabetes. Am J Transplant 2008;8:2463-70
13. Jaeger C, Brendel MD, Hering BJ, et al. IA-2 antibodies are only positive in association with GAD 65 and islet cell antibodies in islet transplanted insulin-dependent diabetes mellitus patients. Transplant Proc 1998;30:659-60
14. Bosi E, Braghi S, Maffi P, et al. Autoantibody response to islet transplantation in type 1 diabetes. Diabetes 2001;50:2464-71
15. Pinkse GGM, Tysma OHM, Bergen CAM, et al. Autoreactive CD8 T cells associated with beta cell destruction in type 1 diabetes. Proc Natl Acad Sci USA 2005;102:18425-30
16. Toso C, Edgar R, Pawlick R, et al. Effect of different induction strategies on effector, regulatory and memory lymphocyte sub-populations in clinical islet transplantation. Transpl Int 2009;22:182-91
17. Eriksson O, Eich T, Sundin A, et al. Positron emission tomography in clinical islet transplantation. Am J Transplant 2009;9:2816-24
18. Biarnes M, Montolio M, Nacher V, et al. Beta-cell death and mass in syngeneically transplanted islets exposed to short- and long-term hyperglycemia. Diabetes 2002;51:66-72
19. Kaddis JS, Danobeitia JS, Niland JC, et al. Multicenter analysis of novel and established variables associated with successful human islet isolation outcomes. Am J Transplant 2010;10:646-56
20. Toso C, Oberholzer J, Ris F, et al. Factors affecting human islet of Langerhans isolation yields. Transplant Proc 2002;34:826-7
21. Lakey JRT, Kneteman NM, Rajotte RV, et al. Effect of core pancreas temperature during cadaveric procurement on human islet isolation and functional viability. Transplantation 2002;73:1106-10
22. Baertschiger RM, Berney T, Morel P. Organ preservation in pancreas and islet transplantation. Curr Opin Organ Transplant 2008;13:59-66
23. Noguchi H, Naziruddin B, Onaca N, et al. Comparison of modified Celsior solution and M-Kyoto solution for pancreas preservation in human islet isolation. Cell Transplant 2010;19:751-8
24. Hammar E, Parnaud G, Bosco D, et al. Extracellular matrix protects pancreatic beta-cells against apoptosis: Role of short- and long-term signaling pathways. Diabetes 2004;53:2034-41
25. Parnaud G, Hammar E, Rouiller DG, et al. Blockade of beta 1 integrin-laminin-5 interaction affects spreading and insulin secretion of rat beta-cells attached on extracellular matrix. Diabetes 2006;55:1413-20
26. Johansson U, Olsson A, Gabrielsson S, et al. Inflammatory mediators expressed in human islets of Langerhans: Implications for islet transplantation. Biochem Biophys Res Commun 2003;308:474-9
27. Lund T, Mangsbo SM, Scholz H, et al. Resolvin E1 reduces proinflammatory markers in human pancreatic islets in vitro. Exp Clin Endocrinol Diabetes 2010;118:237-44
28. Johansson H, Lukinius A, Moberg L, et al. Tissue factor produced by the endocrine cells of the islets of Langerhans is associated with a negative outcome of clinical islet transplantation. Diabetes 2005;54:1755-62
29. Moberg L, Johansson H, Lukinius A, et al. Production of tissue factor by pancreatic islet cells as a trigger of detrimental thrombotic reactions in clinical islet transplantation. Lancet 2002;360:2039-45
30. Johansson H, Goto M, Dufrane D, et al. Low molecular weight dextran sulfate: A strong candidate drug to block IBMIR in clinical islet transplantation. Am J Transplant 2006;6:305-12
31. Merani S, Toso C, Emamaullee J, Shapiro AMJ. Optimal implantation site for pancreatic islet transplantation. Br J Surg 2008;95:1449-61
32. Moberg L, Korsgren O, Nilsson B. Neutrophilic granulocytes are the predominant cell type infiltrating pancreatic islets in contact with ABO-compatible blood. Clin Exp Immunol 2005;142:125-31
33. Moberg L, Olsson A, Berne C, et al. Nicotinamide inhibits tissue factor expression in isolated human pancreatic islets: Implications for clinical islet transplantation. Transplantation 2003;76:1285-8
34. Lund T, Fosby B, Korsgren O, et al. Glucocorticoids reduce pro-inflammatory cytokines and tissue factor in vitro and improve function of transplanted human islets in vivo. Transpl Int 2008;2:669-78
35. Piemonti L, Leone BE, Nano R, et al. Human pancreatic islets produce and secrete MCP-1/CCL2: Relevance in human islet transplantation. Diabetes 2002;51:55-65
36. Lai Y, Chen C, Linn T. Innate immunity and heat shock response in islet transplantation. Clin Exp Immunol 2009;157:1-8
37. Bottino R, Balamurugan AN, Tse H, et al. Response of human islets to isolation stress and the effect of antioxidant treatment. Diabetes 2004;53:2559-68
38. Toso C, Serre-Beinier V, Emamaullee J, et al. The role of macrophage migration inhibitory factor in mouse islet transplantation. Transplantation 2008;86:1361-9
39. Davalli AM, Scaglia L, Zangen DH, et al. Vulnerability of islets in the immediate posttransplantation period. Dynamic changes in structure and function. Diabetes 1996;45:1161-7
40. Montolio M, Biarnes M, Tellez N, et al. Interleukin-1beta and inducible form of nitric oxide synthase expression in early syngeneic islet transplantation. J Endocrinol 2007;192:169-77
41. Andres A, Toso C, Morel P, et al. Macrophage depletion prolongs discordant but not concordant islet xenograft survival. Transplantation 2005;79:543-9
42. Bottino R, Fernandez LA, Ricordi C, et al. Transplantation of allogeneic islets of Langerhans in the rat liver: Effects of macrophage depletion on graft survival and microenvironment activation. Diabetes 1998;47:316-23
43. Toso C, Pawlick R, Lacotte S, et al. Detecting rejection after mouse islet transplantation utilizing islet protein-stimulated ELISPOT. Cell Transplantation (In press)
44. Riethmuller S, Ferrari-Lacraz S, Muller MK, et al. Donor-specific antibody levels and three generations of crossmatches to predict antibody-mediated rejection in kidney transplantation. Transplantation 2010;90:160-7
45. Mohanakumar T, Narayanan K, Desai N, et al. A significant role for histocompatibility in human islet transplantation. Transplantation 2006;82:180-7
46. Ferrari-Lacraz S, Berney T, Morel P, et al. Low risk of anti-human leukocyte antigen antibody sensitization after combined kidney and islet transplantation. Transplantation 2008;86:357-9
47. Campbell PM, Senior PA, Salam A, et al. High risk of sensitization after failed islet transplantation. Am J Transplant 2007;7:2311-17
48. Cardani R, Pileggi A, Ricordi C, et al. Allosensitization of islet allograft recipients. Transplantation 2007;84:1413-27
49. Olack BJ, Swanson CJ, Flavin KS, et al. Sensitization to HLA antigens in islet recipients with failing transplants. Transplant Proc 1997;29:2268-9
50. Lobo PI, Spencer C, Simmons WD, et al. Development of anti-human leukocyte antigen class 1 antibodies following allogeneic islet cell transplantation. Transplant Proc 2005;37:3438-40
51. Rickels MR, Kamoun M, Kearns J, et al. Evidence for allograft rejection in an islet transplant recipient and effect on beta-cell secretory capacity. J Clin Endocrinol Metab 2007;92:2410-14
52. Kessler L, Parissiadis A, Bayle F, et al. Evidence for humoral rejection of a pancreatic islet graft and rescue with rituximab and IV immunoglobulin therapy. Am J Transplant 2009;9:1961-6
53. Tuomilehto J, Zimmet P, Mackay IR, et al. Antibodies to glutamic acid decarboxylase as predictors of insulin-dependent diabetes mellitus before clinical onset of disease. Lancet 1994;343:1383-5
54. Verge CF, Gianani R, Kawasaki E, et al. Number of autoantibodies (against insulin, GAD or ICA512/IA2) rather than particular autoantibody specificities determines risk of type I diabetes. J Autoimmun 1996;9:379-83
55. Hilbrands R, Huurman VAL, Gillard P, et al. Differences in baseline lymphocyte counts and autoreactivity are associated with differences in outcome of islet cell transplantation in type 1 diabetic patients. Diabetes 2009;58:2267-76
56. Jaeger C, Hering BJ, Hatziagelaki E, et al. Glutamic acid decarboxylase antibodies are more frequent than islet cell antibodies in islet transplanted IDDM patients and persist or occur despite immunosuppression. J Mol Med 1999;77:45-8
57. Keymeulen B, Ling Z, Gorus FK, et al. Implantation of standardized beta-cell grafts in a liver segment of IDDM patients: Graft and recipients characteristics in two cases of insulin-independence under maintenance immunosuppression for prior kidney graft. Diabetologia 1998;41:452-9
58. Hering BJ, Kandaswamy R, Ansite JD, et al. Single-donor, marginal-dose islet transplantation in patients with type 1 diabetes. JAMA 2005;293:830-5
59. Martin S, Wolf-Eichbaum D, Duinkerken G, et al. Development of type 1 diabetes despite severe hereditary B-lymphocyte deficiency. N Engl J Med 2001;345:1036-40
60. van Kampen CA, van de Linde P, Duinkerken G, et al. Alloreactivity against repeated HLA mismatches of sequential islet grafts transplanted in non-uremic type 1 diabetes patients. Transplantation 2005;80:118-26
61. Huurman VAL, Hilbrands R, Pinkse GGM, et al. Cellular islet autoimmunity associates with clinical outcome of islet cell transplantation. PLoS ONE 2008;3:e2435
62. Huurman VAL, Velthuis JHL, Hilbrands R, et al. Allograft-specific cytokine profiles associate with clinical outcome after islet cell transplantation. Am J Transplant 2009;9:382-8
63. Stobbe I, Duinkerken G, van Rood JJ, et al. Tolerance to kidney allograft transplanted into type I diabetic patients persists after in vivo challenge with pancreatic islet allografts that express repeated mismatches. Diabetologia 1999;42:1379-80
64. Roelen DL, Huurman VAL, Hilbrands R, et al. Relevance of cytotoxic alloreactivity under different immunosuppressive regimens in clinical islet cell transplantation. Clin Exp Immunol 2009;156:141-8
65. Roelen DL, van Bree FP, Schanz U, et al. Differential inhibition of primed alloreactive CTLs in vitro by clinically used concentrations of cyclosporine and FK506. Transplantation 1993;56:190-5
66. Velthuis JH, Unger WW, Abreu JRF, et al. Simultaneous detection of circulating autoreactive CD8+ T-cells specific for different islet cell-associated epitopes using combinatorial MHC multimers. Diabetes 2010;59:1721-30
67. Vendrame F, Pileggi A, Laughlin E, et al. Recurrence of type 1 diabetes after simultaneous pancreas-kidney transplantation, despite immunosuppression, is associated with autoantibodies and pathogenic autoreactive CD4 T-cells. Diabetes 2010;59:947-57
68. Kowalski RJ, Post DR, Mannon RB, et al. Assessing relative risks of infection and rejection: A meta-analysis using an immune function assay. Transplantation 2006;82:663-8
69. Cabrera R, Ararat M, Soldevila-Pico C, et al. Using an immune functional assay to differentiate acute cellular rejection from recurrent hepatitis C in liver transplant patients. Liver Transpl 2009;15:216-22
70. Husain S, Raza K, Pilewski JM, et al. Experience with immune monitoring in lung transplant recipients: Correlation of low immune function with infection. Transplantation 2009;87:1852-7
71. Han D, Xu X, Baidal D, et al. Assessment of cytotoxic lymphocyte gene expression in the peripheral blood of human islet allograft recipients: Elevation precedes clinical evidence of rejection. Diabetes 2004;53:2281-90
72. Ritz-Laser B, Oberholzer J, Toso C, et al. Molecular detection of circulating beta-cells after islet transplantation. Diabetes 2002;51:557-61
73. Berney T, Mamin A, James Shapiro AM, et al. Detection of insulin mRNA in the peripheral blood after human islet transplantion predicts deterioration of metabolic control. Am J Transplant 2006;6:1704-11
74. Gagne K, Brouard S, Giral M, et al. Highly altered V beta repertoire of T cells infiltrating long-term rejected kidney allografts. J Immunol 2000;164:1553-63
75. Brouard S, Mansfield E, Braud C, et al. Identification of a peripheral blood transcriptional biomarker panel associated with operational renal allograft tolerance. Proc Natl Acad Sci USA 2007;104:15448-53
76. Gunther OP, Balshaw RF, Scherer A, et al. Functional genomic analysis of peripheral blood during early acute renal allograft rejection. Transplantation 2009;88:942-51
77. Pelzl S, Opelz G, Daniel V, et al. Evaluation of posttransplantation soluble CD30 for diagnosis of acute renal allograft rejection. Transplantation 2003;75:421-3
78. Langan LL, Park LP, Hughes TL, et al. Post-transplant HLA class II antibodies and high soluble CD30 levels are independently associated with poor kidney graft survival. Am J Transplant 2007;7:847-56
79. Saini D, Ramachandran S, Nataraju A, et al. Activated effector and memory T cells contribute to circulating sCD30: Potential marker for islet allograft rejection. Am J Transplant 2008;8:1798-808
80. Hire K, Hering B, Bansal-Pakala P. Relative reductions in soluble CD30 levels post-transplant predict acute graft function in islet allograft recipients receiving three different immunosuppression protocols. Transpl Immunol 2010;23:209-14
81. Kurata Y, Kato M, Kuzuya T, et al. Pretransplant pharmacodynamic analysis of immunosuppressive agents using CFSE-based T-cell proliferation assay. Clin Pharmacol Ther 2009;86:285-9
82. Friedl P, den Boer AT, Gunzer M. Tuning immune responses: Diversity and adaptation of the immunological synapse. Nat Rev Immunol 2005;5:532-45
83. Toso C, Shapiro AMJ, Bowker S, et al. Quality of life after islet transplant: Impact of the number of islet infusions and metabolic outcome. Transplantation 2007;84:664-6
84. Benhamou PY, Milliat-Guittard L, Wojtusciszyn A, et al. Quality of life after islet transplantation: Data from the GRAGIL 1 and 2 trials. Diabet Med 2009;26:617-21
85. Andree H, Nickel P, Nasiadko C, et al. Identification of dialysis patients with panel-reactive memory T cells before kidney transplantation using an allogeneic cell bank. J Am Soc Nephrol 2006;17:573-80
86. Nickel P, Presber F, Bold G, et al. Enzyme-linked immunosorbent spot assay for donor-reactive interferon-gamma-producing cells identifies T-cell presensitization and correlates with graft function at 6 and 12 months in renal-transplant recipients. Transplantation 2004;78:1640-6
87. Toso C, Zaidi H, Morel P, et al. Positron-emission tomography imaging of early events after transplantation of islets of Langerhans. Transplantation 2005;79:353-5
88. Toso C, Vallee J, Morel P, et al. Clinical magnetic resonance imaging of pancreatic islet grafts after iron nanoparticle labeling. Am J Transplant 2008;8:701-6
89. Eich T, Eriksson O, Lundgren T. Visualization of early engraftment in clinical islet transplantation by positron-emission tomography. N Engl J Med 2007;356:2754-5
90. Toso C, Isse K, Demetris A, et al. Histologic graft assessment after clinical islet transplantation. Transplantation 2009;88:1286-93
91. Open-label investigation of the safety and effectiveness of DIABECELL(R) in patients with type i diabetes mellitus. Bethesda MD: ClinicalTrials.gov, 2010. Available from: Http://clinicaltrials. gov/ct2/show/NCT00940173? term=DIABECELL&rank=1 [Last accessed 1 November 2010]
92. Safety and efficacy study of encapsulated human islets allotransplantation to treat type 1 diabetes. Bethesda MD: ClinicalTrials.gov, 210. Available from: Http://clinicaltrials.gov/ct2/show/ NCT00790257?term=islet+ encapsulation&rank=1 [Last accessed 1 November 2010]
93. Veriter S, Mergen J, Goebbels R, et al. In vivo selection of biocompatible alginates for islet encapsulation and subcutaneous transplantation. Tissue Eng Part A 2010;16:1503-13
94. De Carlo E, Baiguera S, Conconi MT, et al. Pancreatic acellular matrix supports islet survival and function in a synthetic tubular device: In vitro and in vivo studies. Int J Mol Med 2010;25:195-202
95. Krishnamurthy M, Wang R. Integrins and extracellular matrices in pancreatic tissue engineering. Front Biosci (Schol Ed) 2009;1:477-91
96. Augustine JJ, Siu DS, Clemente MJ, et al. Pre-transplant IFN-gamma ELISPOTs are associated with post-transplant renal function in African American renal transplant recipients. Am J Transplant 2005;5:1971-5